Gene Expression Profile Associated with Response to Doxorubicin-Based Therapy in Breast Cancer

Folgueira, Maria Aparecida Azevedo Koike; Carraro, Dirce Maria; Brentani, Helena; Patrão, Diogo Ferreira da Costa; Barbosa, Eduardo C. M.; Netto, Mário Mourão; Caldeira, José Roberto Fígaro; Katayama, Maria Lúcia Hirata; Soares, Fernando Augusto; Oliveira, Conceição Maria de; Reis, Luiz F. L.; Kaiano, Jane Haruko Lima; Camargo, Luiz Octávio de Lima; Vêncio, Ricardo Zorzetto Nicoliello; Snitcovsky, I.; Makdissi, Fabiana Baroni Alves; Silva, Paulo J. S.; Góes, João Carlos Guedes Sampaio; Brentani, Maria Mitzi

doi:10.1158/1078-0432.ccr-04-0548

Cited by 178 publications

(123 citation statements)

References 31 publications

Supporting

Mentioning

109

Contrasting

Unclassified

Order By: Relevance

“…A previous study showed that CLPTM1L was an up-regulated transcript in cisplatin-resistant ovarian tumor cell lines (Yamamoto et al, 2001). Interestingly, it was found that the CLPTM1 homolog was expressed at higher levels in doxorubicin-resistant breast cancer (Folgueira et al, 2005). Recently, a genetic variant within the CLPTM1L gene (rs402710) was shown to be associated with the accumulation of DNA adducts in lung tissue adjacent to tumors (Zienolddiny et al, 2009).…”

Section: A B Discussionmentioning

confidence: 99%

Decreased risk of developing lung cancer in subjects carrying the CLPTM1L rs401681 (G>A) polymorphism: evidence from a meta-analysis

Zhang¹,

Zhang²,

Zhang³

et al. 2014

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT.A genome-wide association study revealed that a single nucleotide polymorphism, CLPTM1L -rs401681 (G>A), located at the 5p15.33 locus was significantly associated with increased risk of various cancers; however, its association with lung cancer is currently inconclusive. In order to explore the relationship between this polymorphism and lung cancer risk more precisely, we performed a meta-analysis of eight eligible studies involving 9935 cases and 11,261 controls. The pooled odds ratio (OR) and the 95% confidence interval (CI) were calculated using a fixedor random-effect models. Results indicated that this polymorphism was significantly associated with lung cancer risk in all genetic models (GA ). An analysis stratified by ethnicity and source of controls revealed a significantly decreased risk among European groups and population-based studies in all genetic models, and among Asian populations only in the dominant model comparison. Additionally, in a subgroup analysis by histology type, the CLPTM1L rs401681 polymorphism was found to significantly decrease the risks of both adenocarcinoma and squamous cell carcinoma of the lung in all genetic models. In conclusion, our study indicated that the CLPTM1L -rs401681 (G>A) polymorphism was significantly associated with decreased lung cancer risk, especially among European populations. Due to some minor limitations, our findings should be confirmed in further studies.

show abstract

Section: A B Discussionmentioning

confidence: 99%

Decreased risk of developing lung cancer in subjects carrying the CLPTM1L rs401681 (G>A) polymorphism: evidence from a meta-analysis

Zhang¹,

Zhang²,

Zhang³

et al. 2014

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…These signatures comprise known signatures such as the genomic grade index as well as several new classifiers [25][26][27][28][29][30][31][32][33][34][35][36][37]. Additional data to support the predictive potential for the 70-gene assay comes from the neoadjuvant study of Straver et al [38].…”

Section: Discussionmentioning

confidence: 99%

The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer

Knauer

Mook

Rutgers

et al. 2010

Breast Cancer Res Treat

241

131

View full text Add to dashboard Cite

International audienceMultigene assays have been developed and validated to determine the prognosis of breast cancer. In this study, we assessed the additional predictive value of the 70-gene MammaPrint signature for chemotherapy (CT) benefit in addition to endocrine therapy (ET) from pooled study series. For 541 patients who received either ET ( = 315) or ET + CT ( = 226), breast cancer-specific survival (BCSS) and distant disease-free survival (DDFS) at 5 years were assessed separately for the 70-gene high and low risk groups. The 70-gene signature classified 252 patients (47%) as low risk and 289 (53%) as high risk. Within the 70-gene low risk group, BCSS was 97% for the ET group and 99% for the ET + CT group at 5 years with a non-significant univariate hazard ratio (HR) of 0.58 (95% CI 0.07–4.98; = 0.62). In the 70-gene high risk group, BCSS was 81% (ET group) and 94% (ET + CT group) at 5 years with a significant HR of 0.21 (95% CI 0.07–0.59; < 0.01). DDFS was 93% (ET) versus 99% (ET + CT), respectively, in the 70-gene low risk group, HR 0.26 (95% CI 0.03–2.02; = 0.20). In the high risk group DDFS was 76 versus 88%, HR of 0.35 (95% CI 0.17–0.71; < 0.01). Results were similar in multivariate analysis, showing significant survival benefit by adding CT in the 70-gene high risk group. A significant and clinically meaningful benefit was observed by adding chemotherapy to endocrine treatment in 70-gene high risk patients. This benefit was not significant in low risk patients, who were at such low risk for recurrence and cancer-related death, that adding CT does not appear to be clinically meaningful

show abstract

“…16,17 PBEF1 overexpression has also been shown to predict poor response to doxorubicin-based primary chemotherapy in breast cancer patients. 18 Further, NAD + , the final product of salvage pathway catalyzed by NAmPRTase, is an essential coenzyme that is also used as a substrate in several biochemical reactions, such as those catalyzed by poly (ADP-ribose) polymerase (PARP1), sirtuins and ADP-ribosyl cyclase. 19 In particular, NAmPRTase, the rate-limiting component in the NAD + biosynthesis pathway, regulates the function of the Sir2 ortholog, Sirt1, in mammalian cells.…”

Section: Discussionmentioning

confidence: 99%

PBEF1/NAmPRTase/Visfatin: A potential malignant astrocytoma/glioblastoma serum marker with prognostic value

Reddy¹,

Srikantha²,

Thota³

et al. 2008

Cancer Biology & Therapy

View full text Add to dashboard Cite

Malignant astrocytomas comprise anaplastic astrocytoma (AA; grade III) and Glioblastoma (GBM; grade IV). GBM is the most malignant with a median survival of 10-12 months in patients. Using cDNA microarray based expression profiling of different grades of astrocytomas, we identified several fold increased levels of PBEF1 transcripts in GBM samples. Pre-B-cell colony enhancing factor 1 gene (PBEF1) encodes Nicotinamide phosphoribosyltransferase (NAmPRTase), which catalyses the rate limiting step in the salvage pathway of NAD metabolism in mammalian cells. Further validation using real time RT-qPCR on an independent set of tumor samples (n = 91) and normal brain samples (n = 9), GBM specific higher expression of PBEF1 was confirmed. Immunohistochemical staining for PBEF1 on a subset of the above samples largely reinforced our finding. We carried out ELISA analysis on serum samples of astrocytoma patients to determine whether this protein levels would correlate with the presence of tumor and tumor grade. PBEF1 serum levels were substantially elevated in many of the AA and GBM patients. Statistical analysis of these data indicates that in patients with astrocytoma, serum PBEF1 levels correlate with tumor grade and is highest in GBM. Immunohistochemical analysis of an independent set of 51 retrospective GBM cases with known survival data revealed that PBEF1 expression in the tumor tissue along with its co-expression with p53 was associated with poor survival. Thus, we have identified PBEF1 as a potential malignant astrocytoma serum marker and prognostic indicator among GBMs.

show abstract

Gene Expression Profile Associated with Response to Doxorubicin-Based Therapy in Breast Cancer

Abstract: A trio of genes might potentially distinguish doxorubicin-responsive from nonresponsive tumors, but further validation by a larger number of samples is still needed.

Cited by 178 publications

References 31 publications

Decreased risk of developing lung cancer in subjects carrying the CLPTM1L rs401681 (G>A) polymorphism: evidence from a meta-analysis

Decreased risk of developing lung cancer in subjects carrying the CLPTM1L rs401681 (G>A) polymorphism: evidence from a meta-analysis

The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer

PBEF1/NAmPRTase/Visfatin: A potential malignant astrocytoma/glioblastoma serum marker with prognostic value

Contact Info

Product

Resources

About